NCT01531361 2021-01-22
Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations
M.D. Anderson Cancer Center
Phase 1 Completed
Clinical Trials
9 trialsNCT01767623 2018-02-13
A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Participants
Hoffmann-La Roche
Phase 1 Completed
NCT02441465 2017-11-14
Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies
Hoffmann-La Roche
Phase 1 Completed
NCT01765543 2016-12-15
A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)
Hoffmann-La Roche
Phase 1 Completed
NCT01849666 2016-11-02
A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy
Hoffmann-La Roche
Phase 1 Completed
NCT01851824 2016-11-02
A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy
Hoffmann-La Roche
Phase 1 Completed
NCT01974258 2016-11-02
Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients
Hoffmann-La Roche
Phase 1 Withdrawn
NCT01765569 2015-09-23
A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma
Hoffmann-La Roche
Phase 1 Completed
NCT01673737 2015-04-10
A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer
Sanofi
Phase 1 Completed